Clinical value of a new TSH binding inihibitory activity assay using human TSH receptors in the follow-up of antithyroid drug treated Graves' disease. Comparison with thyroid stimulating antibody bioassay

Clinical Endocrinology

Volumn 54, Issue 1, 2001, Pages 89-96

  Maugendre, D ^a   Massart, C ^b  

^a SERVICE DE RHUMATOLOGIE   (France)

^b PONTCHAILLOU UNIVERSITY HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHYROID AGENT; CARBIMAZOLE; THYROID STIMULATING IMMUNOGLOBULIN; THYROTROPIN; THYROTROPIN RECEPTOR;

ADOLESCENT; ADULT; AGED; ARTICLE; BIOASSAY; CELL CULTURE; DRUG WITHDRAWAL; FEMALE; FOLLOW UP; GRAVES DISEASE; HORMONE BINDING; HUMAN; HUMAN CELL; HYPERTHYROIDISM; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELAPSE; REMISSION;

ADOLESCENT; ADULT; AGED; ANTITHYROID AGENTS; AUTOANTIBODIES; CARBIMAZOLE; CHI-SQUARE DISTRIBUTION; FEMALE; GRAVES DISEASE; HUMANS; IMMUNOGLOBULINS, THYROID-STIMULATING; MALE; PREDICTIVE VALUE OF TESTS; RECEPTORS, THYROTROPIN; RECURRENCE; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; THYROID GLAND; TIME FACTORS; TREATMENT OUTCOME; TRIIODOTHYRONINE;

EID: 0035134529     PISSN: 03000664     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2265.2001.01197.x     Document Type: Article

References (39)

1. Age and gender predict the outcome of treatment for Graves' hyperthyroidism
2. Antithyroid drugs and Graves' disease: A prospective randomized evaluation of the efficacy of treatment duration
3. Second generation assay for thyrotropin receptor antibodies has superior diagnostic sensitivity for Graves' disease
4. Binding assay for thyrotropin receptor autoantibodies using the recombinant receptor protein
5. Thyroid controversy-stimulating antibodies
6. Optimum duration of antithyroid drug treatment determined by assay of thyroid stimulating antibody in patients with Graves' disease
7. Meta-analysis evaluation of the impact of thyrotropin receptor antibodies on long term remission after medical therapy of Graves' disease
8. Recombinant human thyrotropin (TSH) receptor in a radioreceptor assay for the measurement of, T.S.H. & receptor autoantibodies
9. Thyrotropin receptor antibodies: Advances and importance of detection techniques in thyroid disease
10. Administration of thyroxine in treated Graves' disease. Effects on the level of antibodies to thyroid-stimulating hormone receptors and on the risk of recurrence of hyperthyroidism
11. Prediction of relapse in drug-treated Graves' disease using thyroid stimulation indices
12. Hyperthyroid Graves' disease without detectable thyrotropin receptor antibodies
13. The human thyrotropin (TSH) receptor in a TSH binding inhibition assay for TSH receptor autoantibodies
14. Thyroid histology of hyperthyroid Graves' disease with undetectable thyrotropin receptor antibodies
15. Effect of thyroxine administration on serum thyrotropin receptor antibody and thyroglobulin levels in patients with Graves' hyperthyroidism during antithyroid drug therapy
16. Goitre size and outcome of medical treatment of Graves' disease
17. Medical therapy of Graves' disease: Does thyroxine prevent recurrence of hyperthyroidism?
18. Thyroid stimulating antibodies: An aid to the strategy of treatment of Graves' disease?
19. Use of chinese hamster ovary cell lines transfected with cloned human thyrotropin receptor for the measurement of thyroid-stimulating antibodies: Advantages and difficulties
20. Assays for thyrotropin-receptor binding and thyroid-stimulating antibodies in sera from patients with Graves' disease
21. Antithyroid drugs and Graves' disease-prospective randomized assessment of long-term treatment
22. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug
23. Clinical review 3: The clinical use of thyrotropin receptor antibody measurements
24. Measurement of thyroid stimulating immunoglobulins in a new cell line transfected with a functional human TSH receptor (JP09 cells) compared with an assay using FRTL-5 cells
25. The prognostic value of thyrotropin receptor antibody measurement in the early stages of treatment of Graves' disease with antithyroid drugs
26. Application of a bioassay with CHO cells for the routine detection of stimulating and blocking autoantibodies to the TSH-receptor
27. Immunological findings and thyroid function of untreated Graves' disease patients with undetectable TSH-binding inhibitor immunoglobulin
28. Auto-antibodies to the thyrotropin receptor
29. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease
30. Effect of methimazole with or without exogenous L-thyroxine on serum concentrations of thyrotropin (TSH) receptor antibodies in patients with Graves' disease
31. Comparison of effects of high and low dosage regimens of antithyroid drugs in the management of Graves' hyperthyroidism
32. Prospective multicentre study on the prediction of relapse after antithyroid drug treatment in patients with Graves' disease
33. An improved radioreceptor assay for TSH receptor antibodies
34. Lack of effect of thyroxine administration on elevated thyroid stimulating hormone receptor antibody levels in treated Graves' disease patients
35. Iodine deficiency in France
36. Clinical features of patients with Graves' disease undergoing remission after antithyroid drug treatment
37. Autoimmune thyroid disease: Further developments in our understanding
38. The spectrum and significance of autoantibodies reacting with the thyrotropin receptor
39. Simultaneous assay for three types of thyrotropin receptor antibody activities using FRTL-5 cells in patients with autoimmune thyroid diseases